• Phase 3 FRONTIER4 extension data showed positive long-term safety and efficacy for investigational Mim8 (denecimig) across once-weekly, biweekly, and monthly dosing in hemophilia A patients of all ages.
• Approximately 71% of adults/adolescents and 89% of children experienced zero treated bleeds while receiving Mim8.
• Novo Nordisk also reported Phase 3 explorer10 data showing concizumab reduced annualized bleeding rates by 82% versus prior on-demand treatment in children with hemophilia A or B with inhibitors.